Etokimab

BIOLOGICAL4 trials

Sponsors

AnaptysBio, Inc.

Conditions

Atopic DermatitisChronic RhinosinusitisEosinophilic AsthmaPeanut Allergy

Phase 2

Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy

CompletedNCT02920021

AnaptysBio, Inc.Peanut Allergy

Start: 2017-01-26End: 2018-03-30Updated: 2023-07-27

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

CompletedNCT03469934

AnaptysBio, Inc.Eosinophilic Asthma

Start: 2017-11-14End: 2018-10-30Updated: 2023-08-16

Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

CompletedNCT03533751

AnaptysBio, Inc.Atopic Dermatitis

Start: 2018-06-19End: 2019-12-03Updated: 2023-05-24

Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

CompletedNCT03614923

AnaptysBio, Inc.Chronic Rhinosinusitis

Start: 2018-11-29End: 2020-10-26Updated: 2022-01-24

Related Papers

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials

Clinical and Translational Science2024-07-309 citations

Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy

JCI Insight2019-11-14181 citations